KR20160146470A

KR20160146470A - Blister package and manufacturing method thereof

Info

Publication number: KR20160146470A
Application number: KR1020150137731A
Authority: KR
Inventors: 오동헌; 이정효; 이기형; 이정열; 김인태
Original assignee: 오동헌; 이기형; 이정효; 이정열; 김인태
Priority date: 2015-06-11
Filing date: 2015-09-30
Publication date: 2016-12-21
Also published as: KR20160146469A

Abstract

Provided is a blister package including a QR code that identifies medicaments. According to one aspect, the blister package includes; a receiving part that receives medicaments; and a blister sheet coupled to the opening of the receiving part to seal medicaments, and including a QR code for identifying the medicaments. According to another aspect, the blister package comprises: a receiving part receiving medicaments and including a QR code for identifying medicaments; and a blister sheet coupled to the opening of the receiving part to seal the medicaments.

Description

[0001] BLISTER PACKAGE AND MANUFACTURING METHOD THEREOF [0002]

The present invention relates to a blister package and a manufacturing method thereof, and more particularly to a blister package including a QR code for identifying a drug and a manufacturing method thereof.

Most of the ongoing clinical trials are proceeding with oral medications. As it is known, the cause of failure of most clinical trials is due to the failure of the corresponding experiment according to the scheduled clinical trial protocol. Conventionally, in order to confirm the procedure of clinical trials and to collect the results, subjects were given clinical records from hospitals distributing medicines, and the subjects themselves were administered directly from outside the hospital, and the results were evaluated. In the above clinical trial structure, it is very difficult to control the exact progress of the clinical trial because it confirms the medication administration procedure and result depending on the date on which the subject himself wrote.

Because each drug participant in the trial is different and the corresponding schedule for the dosing protocol may be different, the correct drug should be distributed to the correct subject, and the subject should be able to select the correct individual drug There is a need for a package of medicaments that can be administered.

According to one aspect, a blister package is provided in which a QR code for identifying a medicament is placed in a blister sheet. The blister package may include a receiving portion for receiving a medicine, and a blister sheet connected to an opening surface of the receiving portion to seal the medicine, and a QR code for identifying the medicine. According to one embodiment, the blister sheet may include the QR code including first identification data indicating a pharmaceutical company of the drug, and second identification data indicating whether the drug is penalized. In addition, the blister sheet may include a QR code including third identification data for authenticating a subject to be administered with the drug.

According to another aspect, there is provided a blister package comprising a receptacle for receiving a medicament and identifying the medicament. The blister package may include a receiving part including a QR code for receiving the medicine, identifying the medicine, and a blister sheet coupled to the opening of the receiving part to seal the medicine. According to one embodiment, the blister package may be characterized in that the QR cord is present on the outer surface of the receiving portion. According to another embodiment, the receiving portion is formed of a transparent material allowing the medicine to be observed from the outside, and the blister package is present on the inner surface of the receiving portion. In addition, the receiving portion may be formed of transparent polyethylene terephthalate (PET).

According to another aspect, there is provided a method of manufacturing a pharmaceutical for clinical use. The method may include placing a QR code indicative of a clinical test protocol associated with the medicament in a blister package and sealing the medicament using the blister package. According to one embodiment, disposing the QR code in the blister package of the medicament may comprise placing the QR code on at least one side of the receiving portion that contains the medicament. According to another embodiment, the step of disposing the QR code in the blister package of the medicament is such that the QR cord is detachably attached to the blister package such that at least one of the blister sheets sealing the medicament In a side view.

Figures 1A-1C illustrate an exemplary structure of a blister package according to one embodiment.
2 is a perspective view of a receiving portion associated with a blister sheet according to one embodiment.
3 is a perspective view of a receiving portion associated with a blister sheet according to another embodiment.
4 is a perspective view of a blister sheet combined with a receiving portion according to another embodiment.
5 is a flow diagram of a method of manufacturing a blister package including a QR code according to one embodiment.
6 is an exemplary diagram showing the progress of a clinical test using a blister package including a QR code according to an embodiment.

In the following, some embodiments will be described in detail with reference to the accompanying drawings. However, the scope of the present invention is not limited or limited by these embodiments. Like reference symbols in the drawings denote like elements.

The terms used in the following description are chosen to be generic and universal in the art to which they are related, but other terms may exist depending on the development and / or change in technology, customs, preferences of the technician, and the like. Accordingly, the terminology used in the following description should not be construed as limiting the technical thought, but should be understood in the exemplary language used to describe the embodiments.

Also, in certain cases, there may be a term chosen arbitrarily by the applicant, in which case the meaning of the detailed description in the corresponding description section. Therefore, the term used in the following description should be understood based on the meaning of the term, not the name of a simple term, and the contents throughout the specification.

Figures 1A-1C illustrate an exemplary structure of a blister package according to one embodiment. 1A-1C illustrate a blister package 100 that includes a blister sheet 120 that is temporarily attachable to a receiving portion 110 and a receiving portion 110. The blister package 120 is shown in Fig. The receptacle 110 and the blister sheet 120 may be heat treated to seal the medicament during the manufacture of the blister package 100. Illustratively, the heat treatment can be either thermal welding, ultrasonic welding or induction welding.

1B, the receptacle 110 may include at least one hole 111, 112, 113, 114, 115, 116 for receiving a medicament. Each of the at least one hole (111, 112, 113, 114, 115, 116) can receive the medicine. In one embodiment, the received medicament may be a capsule medicament filled or coated with the capsule in the form of at least one of liquid, suspended tablet, pulp, powder, granule. In another embodiment, the received medicament may be a powders medicament, which is implemented in the form of at least one of a powder and a particulate. In another embodiment, the medicament to be received may be a tablet medicament obtained by compression-molding powdery or crystalline medicinal material into a predetermined shape. In addition, the description of the above-described form of the medicinal product is merely an example, and it should be understood that the scope of the present invention is not limited to or limited by the scope of the present invention, and that the present invention can be extended to various types of medicaments used today, would.

1C, the blister sheet 120 may include at least one QR code 121, 122, 123, 124, 125, 126 for identifying each of the at least one medicament. More specifically, the at least one QR code 121, 122, 123, 124, 125, and 126 may be a Quick Response Code in the form of a two-dimensional matrix including various data in a rectangular horizontal and vertical grid pattern space. The blister sheet 120 may include first identification data indicating the pharmaceutical company of the medicament in the at least one QR code 121, 122, 123, 124, 125, In addition, the blister sheet 120 may include second identification data in the at least one QR code (121, 122, 123, 124, 125, 126) Also, the blister sheet 120 may include third identification data in the at least one QR code 121, 122, 123, 124, 125, 126 to authenticate the subject to medicate the medication. The blister sheet 120 may be embodied in a variety of materials commonly used in today's blister packages, such as plastic films, aluminum foils, paper, and paperboard.

In addition, the blister package 100 according to one embodiment can provide an environment in which patients can follow a dosing protocol, not only in the field of clinical testing, but also in drug administration. By way of illustration, certain patients may be different for morning, evening, and evening medicines, depending on the time of day. In addition, the specific patient may be different from the postprandial administration protocol or the pre-meal administration protocol depending on the food intake. By way of example, the QR code may include data associated with a dosing protocol such as the embodiments described above. If the QR code is recognized by the patient's electronic device, the patient's electronic device may output a message related to the medication protocol to the display of the electronic device. In one embodiment, the message may be in the form of a simple pop-up message indicating whether the medicament to be administered is correct. In another embodiment, the message may be a message again describing the medication protocol for the medicament. In yet another embodiment, the message may be a message relating to action effects, remarks and side effects associated with the medicament. In addition, the above-described electronic apparatus refers to various types of electronic apparatuses capable of recognizing image data today, and may be, for example, any one of a smart phone, a mobile phone, and a tablet computer.

2 is a perspective view of a receiving portion associated with a blister sheet according to one embodiment. Referring to FIG. 2, a receiving portion 200 including any one of a plurality of medicines included in the entire blister package is generally shown. The receptacle 200 according to one embodiment may receive the medicine using a hole structure. In addition, the receptacle 200 may be joined to the blister sheet by thermal bonding or the like. However, the binding may be transient and may be releasably associated with the subject or patient. Also, the receptacle 200 may include an opening 210 structure to maintain the structure of the receptacle 200 in the process of being separated from the blister sheet for opening the medicament. The opening surface 210 provides an area of a predetermined size to be combined with the blister sheet, thereby providing an environment in which the medicine can be stably sealed.

In addition, the receptacle 200 may include a QR code 220 for identifying a medicament. 2 corresponds to an example in which the QR code is disposed on the outer surface of the receptacle 200 as one of the examples in which the QR cord is disposed in the blister sheet. In one embodiment, the QR code 220 may be disposed on at least one outer surface of the receiving portion 200. [ More specifically, when the accommodating portion 200 has a cube shape or a rectangular parallelepiped structure, the outer side surface may be the outer side of at least one surface constituting the cube or the rectangular parallelepiped. The outer surface may be a surface where the receiving portion 200 meets the outside air. Conversely, the inner surface may be the surface where the receiving portion 200 meets internal air or medicines. 2, the opening surface 210 may be formed in a rectangular shape when the receiving portion 200 is implemented as a cube or a rectangular parallelepiped.

However, the structure of the receiving portion 200 such as the above-described cube or rectangular parallelepiped is only an exemplary structure for explaining the present invention, and does not limit or limit the scope of the present invention. In addition, it is obvious to those skilled in the art that the structure of the accommodating portion 200 can be expanded into various shapes such as various polyhedra, hemispheres, or three-dimensional ellipses.

In another embodiment, the receptacle 200 may be implemented as a translucent or opaque plastic to block direct sunlight entering the medicament. In such a case, due to the semitransparent or opaque material of the accommodating portion 200, the medicine inside the accommodating portion 200 may not be seen from the outside of the accommodating portion 200. Therefore, when the accommodating portion 200 is implemented as a translucent or opaque material, the QR code can be disposed on the outer surface of the accommodating portion 200.

3 is a perspective view of a receiving portion associated with a blister sheet according to another embodiment. 3 corresponds to an example in which the QR code is arranged on the inner surface of the accommodating portion 300 as one of the examples in which the QR code is disposed on the blister sheet. 3, the receiving part 300 may be embodied in a hemispherical shape, and the medicines may be accommodated in the internal space of the formed receiving part 300 and may be sealed and stored. In addition, the receiving portion 300 may include an opening surface 310 for stable engagement with the blister sheet. 3, when the receptacle 300 is embodied in a hemispherical shape, the opening surface 310 may be embodied as a circle or an ellipse.

In addition, the receiving portion 300 may be formed of a transparent material. More specifically, the receiving portion 300 may be formed of transparent polyethylene terephthalate (PET). In addition, the receiving portion 300 may be formed of PET material having a thickness of 0.5 mm or more to prevent deformation of the medicine. By using the thickness, it is possible to prevent foreign substances or bacteria from flowing into the accommodating part 300 from outside when the medicine is transported or stored, and to maintain the sealed state. In such a case, the inner space of the accommodating portion 300 can be seen from the outside of the accommodating portion 300 as well. In addition, the receptacle 300 may include a QR code 320 for identifying the medicament contained therein. More specifically, the QR code 320 may be disposed on the inner surface of the accommodating portion 300 when the accommodating portion 300 is formed of a transparent material. The inner surface may be a surface where the receiving portion 300 meets internal air or medicine. In the case where the QR code 320 is disposed inside, it is possible to prevent the QR code 320 existing outside the blister package from being damaged or deteriorated due to time or space movement. Accordingly, the subject or the patient of the clinical trial will be able to use the clinical trial management apparatus with improved system error due to the change of the QR code 320.

4 is a perspective view of a blister sheet combined with a receiving portion according to another embodiment. The blister sheet 400 may include a QR code 410 that identifies the medicament the receiving unit is receiving. The QR code 410 may include at least one data associated with the medicament. In one embodiment, the data may be data associated with a medication delivery protocol. In another embodiment, the data may be data indicative of the dosing time corresponding to the medication schedule. In another embodiment, the data may be data indicating a notice to be perceived by the patient or the subject in administering the medicament. However, not only the above embodiments but also many messages to be transmitted between administrators, patients, and hospitals in the course of administration of medicines and clinical trials are transmitted using the QR code 410 arranged on the blister sheet 400 as above .

The blister sheet 400 may be implemented using any one of a plastic cover film or sheet. The blister sheet 400 and the receiving portion are combined using a method such as heat sealing, and can play a role of protecting the internal medicine from the external environment. In addition, the blister sheet 400 may include a cut surface 420 that is not bonded or bonded to the receptacle. The user for opening the medicine can easily separate the blister sheet 400 from the receiving portion by using the cut surface 420. [ In one embodiment, the data contained in the QR code may need to be output not only before the medication but also after the medication. The user can more conveniently perform an operation of confirming the next dosing schedule or confirming the adverse phenomenon depending on the medication after the administration of the drug using the QR code. However, in the absence of the cut surface 420, the user may have difficulty separating the blister sheet 400 from the medicine, and there is a possibility that the QR code 410 may be damaged in the above process. Accordingly, in accordance with one embodiment of the present invention, blister sheet 400 includes a cut surface 420 such that a user, such as a subject or patient, can use the cut surface 420 to damage the QR code 410 The blister sheet 400 can easily be separated from the receiving portion without the need for the blades.

Figure 5 is a flow chart of a method of manufacturing a pharmaceutical product for clinical trials according to one embodiment. A method 500 for manufacturing a clinical trial drug product may include placing a QR code in a blister package 510 and sealing the drug product using the blister package 520. Step 510 is the step of placing a QR code in the blister package representing the clinical trial protocol associated with the medicament. The clinical trial protocol may include the time of administration of the drug corresponding to the QR code, pre- or post-meal administration, and the like. The administrator can insert information on the complex clinical trial protocol into the QR code and place the QR code in a blister package to expect the effect that the clinical trial protocol information can be delivered to the subject or medicament.

In one embodiment, step 510 may include placing the QR code on at least one side of the receiving portion that contains the medicament. The receiving portion of the blister package may be made of a translucent or opaque material to prevent deterioration, discoloration, etc. of the medicines contained therein. In such a case, in step 510, the QR code may be placed on the outer side of the receptacle. On the other hand, the receiving portion of the blister package may be made of a transparent material, and in this case, the QR code may be disposed on the inner side of the receiving portion. As a result, the data inserted in the QR code can be protected from being damaged even in the case of transporting and transporting the entire blister package.

In another embodiment, step 510 may include placing the QR code on at least one side of the blister sheet of the blister package. The blister sheet may be attached to the blister package so as to be detachable from the blister package. In addition, the blister sheet can seal the medicament and protect it from external bacteria or air by bonding with the receptacle. Step 520 is a step of sealing the medicament using the blister package. More specifically, step 520 may include coupling a receptacle containing a QR cord or a blister sheet comprising a QR cord, and inserting and sealing the medicament in the interior space.

6 is an exemplary diagram showing the progress of a clinical test using a blister package including a QR code according to an embodiment. The subject can use the user terminal 610 to transmit the QR code of the drug corresponding to the clinical trial to the clinical trial management server 620. [ Illustratively, the user terminal 610 may include various types of electronic devices, such as smart phones, cell phones, tablet computers, etc., that are connected to the server via a communication network, including a display that recognizes the QR code and outputs corresponding data Lt; / RTI >

The user terminal 610 may extract the identification data associated with the medicines from the QR code and transmit the extracted identification data to the clinical trial management server 620 through the communication interface. In addition, the communication interface may be a WLAN (Wireless LAN), a WiFi (Wireless Fidelity) Direct, a DLNA (Digital Living Network Alliance), a Wibro (Wireless broadband), a Wimax (World Interoperability for Microwave Access) And a short-range communication interface such as Bluetooth ™, Radio Frequency Identification (RFID), Infrared Data Association (IrDA), UWB (Ultra Wideband), ZigBee and NFC . In addition, the communication interface may represent any interface (e.g., a wired interface) capable of communicating with the outside. In addition, the extracted identification data may include a serial number associated with the medicines, placebo information, and corresponding subject authentication information.

The clinical trial management server 620 may determine whether to proceed with the clinical trial using the received identification data and transmit the determined result data to the user terminal 610. [ The user terminal 610 may output the received result data to the user so that the user can determine whether the current clinical trial is okay.

However, the application example using the QR code of the blister package described in FIG. 6 is only one embodiment, and does not limit or limit the scope of the present invention. Using the QR code of the blister package and the electronic device that transmits and receives the corresponding data, it is possible to control the dosage protocol of outpatient patients, distribute the medicines for clinical trials, And can be extended to various embodiments to the extent that it is obvious to a person skilled in the art.

The embodiments described above may be implemented in hardware components, software components, and / or a combination of hardware components and software components. For example, the devices, methods, and components described in the embodiments may be implemented within a computer system, such as, for example, a processor, a controller, an arithmetic logic unit (ALU), a digital signal processor, such as an array, a programmable logic unit (PLU), a microprocessor, or any other device capable of executing and responding to instructions. The processing device may execute an operating system (OS) and one or more software applications running on the operating system. The processing device may also access, store, manipulate, process, and generate data in response to execution of the software. For ease of understanding, the processing apparatus may be described as being used singly, but those skilled in the art will recognize that the processing apparatus may have a plurality of processing elements and / As shown in FIG. For example, the processing unit may comprise a plurality of processors or one processor and one controller. Other processing configurations are also possible, such as a parallel processor.

The software may include a computer program, code, instructions, or a combination of one or more of the foregoing, and may be configured to configure the processing device to operate as desired or to process it collectively or collectively Device can be commanded. The software and / or data may be in the form of any type of machine, component, physical device, virtual equipment, computer storage media, or device , Or may be permanently or temporarily embodied in a transmitted signal wave. The software may be distributed over a networked computer system and stored or executed in a distributed manner. The software and data may be stored on one or more computer readable recording media.

The method according to an embodiment may be implemented in the form of program instructions that can be executed through various computer means and recorded on a computer readable medium. The computer-readable medium may include program instructions, data files, data structures, and the like, alone or in combination. The program instructions to be recorded on the medium may be those specially designed and configured for the embodiments or may be available to those skilled in the art of computer software. Examples of computer-readable media include magnetic media such as hard disks, floppy disks, and magnetic tape; optical media such as CD-ROMs and DVDs; magnetic media such as floppy disks; Magneto-optical media, and hardware devices specifically configured to store and execute program instructions such as ROM, RAM, flash memory, and the like. Examples of program instructions include machine language code such as those produced by a compiler, as well as high-level language code that can be executed by a computer using an interpreter or the like. The hardware devices described above may be configured to operate as one or more software modules to perform the operations of the embodiments, and vice versa.

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments. For example, it should be understood that the techniques described may be implemented in a different order than the described methods, and / or that components of the described systems, structures, devices, Lt; / RTI > or equivalents, even if it is replaced or replaced. Therefore, other implementations, other embodiments, and equivalents to the claims are also within the scope of the following claims.

Claims

A receiving part for receiving the medicine; And
A blister sheet including a QR code for identifying the medicament,
&Lt; / RTI >

The method according to claim 1,
Wherein the blister sheet includes the QR code including first identification data indicating a pharmaceutical company of the medicine and second identification data indicating whether the medicine is a placebo.

3. The method of claim 2,
Wherein the blister sheet comprises a QR code including third identification data for authenticating a subject to be dosed with the medicament.

A receiving part containing a QR code for accepting the medicines and identifying the medicines; And
A blister sheet which is coupled to the opening face of the accommodating portion and seals the drug,
&Lt; / RTI >

5. The method of claim 4,
Wherein the QR cord is present on the outer surface of the receiving portion.

5. The method of claim 4,
Wherein the receiving portion is formed of a transparent material that allows the medicine to be observed from the outside, and the QR cord is present on the inner side of the receiving portion.

The method according to claim 6,
Wherein the receiving portion is formed of a transparent polyethylene terephthalate (PET) material.

A method for producing a pharmaceutical product for clinical use,
Placing a QR code indicative of a clinical test protocol associated with said medicament in a blister package; And
Sealing the pharmaceutical product using the blister package
&Lt; / RTI >

9. The method of claim 8,
Wherein disposing the QR code in the blister package of the medicament comprises positioning the QR cord on at least one side of the receiving portion that contains the medicament.

9. The method of claim 8,
Wherein disposing the QR code in the blister package of the medicament comprises disposing the QR cord removably attached to the blister package and disposed on at least one side of the blister sheet sealing the medicament How to.